3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic

Highly respected T-cell immunologist brings more than three decades’ experience working across diverse R&D disciplines in T-cell immunology and cancer biology Joining forces is Estelle Marrer-Berger, Ph.D., as chief development officer SOUTH SAN FRANCISCO, Calif., Oct. 25, 2023…

Click here to view original post